Navigation Links
Lesaffre Invests in Intralytix, a US Biotechnology Company
Date:7/24/2017

BALTIMORE, July 24, 2017 /PRNewswire/ --Intralytix, Inc. announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. This investment marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based products, for various benefits in human health and in other areas of mutual interest.

As a global key player in yeasts and fermentation, Lesaffre designs manufactures and markets innovative solutions for baking, food taste & pleasure, health care, and biotechnology. This new investment is perfectly in line with Lesaffre's ongoing expansion strategy in nutrition and health. In 2015, Lesaffre had already announced the investment in Gnosis, an Italian company specialized in ingredients for the pharmaceutical, nutraceutical, cosmetic and veterinary industries.

Alexander Sulakvelidze, Executive Vice President and Chief Scientific Officer of Intralytix commented:"We are delighted to have partnered with Lesaffre. This investment solidifies Intralytix's position as the leader in the field of bacteriophage research and commercialization, and allows us to strengthen the company infrastructure by enhancing our already superb R&D programs, adding high throughput robotic technologies, and expanding our state-of-the-art phage production capabilities."

Antoine Baule, Lesaffre's CEO, added "We believe that bacteriophage technology, mastered by Intralytix, offers an exciting platform for developing various antimicrobial products that will help reduce antibiotic resistance.  Intralytix is the leader in this field, and we look forward to working with their teams, developing new phage-based products and technologies and making them available to benefit customers worldwide."

"We are pleased to partner with Lesaffre and to engage in the development of a series of novel bacteriophage-based products," remarked John Woloszyn, Intralytix's CEO. "Phage-based products, when properly formulated and manufactured, provide a safe, effective and all-natural way to help maintain healthy microbiota. We believe that our collaboration with Lesaffre will significantly enhance and expedite product development and will ultimately benefit hundreds of thousands of people worldwide."

About Lesaffre

As a global key player in yeasts and fermentation, Lesaffre designs manufactures and markets innovative solutions for baking, food taste & pleasure, health care and biotechnology. The family group born in northern France in 1853, now a multi-national and a multicultural company, Lesaffre is committed to working with confidence to better nourish and protect the planet. In close collaboration with its clients and partners, Lesaffre employs 9,500 people in more than 70 subsidiaries, based in about 40 countries.

More information: www.lesaffre.com

About Intralytix, Inc.

Intralytix, Inc. is a privately-held company headquartered in Baltimore, Maryland. The company is the world's leader in bacteriophage technology and was the first company in the world to receive FDA-approval for a phage-based product for food safety applications. Intralytix currently has the largest portfolio in the world of phage-based products in commercial markets. The company holds several bacteriophage technology-related patents, including two U.S. patents (and additional patents pending) for fine-tuning human or animal microbiome by using bacteriophages to reduce or eliminate bacterial colonization.

More information: www.intralytix.com

Press contacts:

For Lesaffre
Vanessa Vazzaz
RP Carrées
Tel : +33 3 28 52 07 4
+33 6 34 32 24 23
vanessa.vazzaz@rp-carrees.co

For Intralytix
Dr. Alexander Sulakvelidze
Executive Vice President
Chief Scientific Officer
Tel. +1 410 625 2533
asulakvelidze@intralytix.com

 

View original content:http://www.prnewswire.com/news-releases/lesaffre-invests-in-intralytix-a-us-biotechnology-company-300493121.html


'/>"/>
SOURCE Intralytix, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Mitsui & Co. Invests Additional $CDN25 Million in BioAmber Sarnia
2. Ratan Tata Invests in Invictus Oncology
3. Goldman Sachs Invests US$20 Million in Ascletis
4. Connecticut Bioscience Innovation Fund Invests $10 Million in Program in Innovative Therapeutics for Connecticut’s Health (PITCH)
5. Portage Invests in Sentien Biotechnologies Inc.
6. Chiye Organic Silicon Material (Shanghai) Co., Ltd Invests USD1.6 Million on Production Plant
7. Infinity Group Invests US$4.2 M in Green BioTech Company BotanoCap
8. AMRESCO Invests in New Powder Manufacturing Facility to Support Growth in Life Science Business
9. Panitch Schwarze Life Sciences Practice Leader Speaks at Biotechnology Conference in Shanghai
10. Separation Systems for Commercial Biotechnology
11. Agricultural Biotechnology - Emerging Technologies & Global Markets - Driving Forces, Market Applications, Industry Structure & Competitive Dynamics - Research and Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2019)... ... January 08, 2019 , ... The American Society of Gene ... named by a selection committee made up of industry leaders identified by the ASGCT ... grants are mentored awards created to support ASGCT members designing transformative pilot studies in ...
(Date:1/4/2019)... ... January 04, 2019 , ... Triangle Insights Group, a ... firm. Ted will be joining the firm as a partner. , Ted ... to the pharmaceutical industry. At Triangle Insights, Ted will apply his deep expertise ...
(Date:1/4/2019)... Calif. (PRWEB) , ... January 02, 2019 , ... ... proprietary technology to detect precancer and cancer cells in blood, has been named ... Biotech , a global biotech company developing cell therapies for cancer treatment, will ...
(Date:12/20/2018)... ... 20, 2018 , ... New Year’s brings reflection and desire to improve for ... European Union (EU) on the horizon, Jim Kasic, president and CEO of Boulder iQ, ... EU Medical Device Regulation (MDR), digital health, and big data are just a few ...
Breaking Biology Technology:
(Date:12/27/2018)... ... December 27, 2018 , ... AxioMed completed ... new Boston facility, and is now raising growth capital to ramp up demand ... share against inferior ball and socket discs. The capital raise is targeted to ...
(Date:12/22/2018)... ... 2018 , ... On Wednesday, Dec. 12, Greenberg Traurig, LLP’s ... Helen Chen, Greater China Managing Partner of L.E.K. Chen shared her insights on ... attorney David J. Dykeman , co-chair of Greenberg Traurig’s global Life ...
(Date:12/19/2018)... ... 19, 2018 , ... InTouchMD’s flagship product, Pulse , has been honored ... , PM360 is featuring the recognition in its 7th annual Innovations issue, created for ... pharmaceutical and medical device industries. , “This recognition comes at an exciting time for ...
Breaking Biology News(10 mins):